A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013

• Main Authors: Siu-Fun Wong (Author), Joseph M. Unger (Author), James L. Wade (Author), Lynne I. Wagner (Author), Mario E. Lacouture (Author), Keisha C. Humphries (Author), Anna Moseley (Author), Kathryn Arnold (Author), Mario R. Velasco (Author), Justin D. Floyd (Author), Benjamin T. Esparaz (Author), Afsaneh Barzi (Author), Heinz-Josef Lenz (Author), Marianna Koczywas (Author), Shaker Dakhil (Author), Gary V. Burton (Author), Michael J. Fisch (Author), N. Lynn Henry (Author), Dawn L. Hershman (Author), Carol M. Moinpour (Author)
• Format: Book
• Published: SpringerOpen, 2020-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Papulopustular rash is a common class effect of epidermal growth factor receptor inhibitors (EGFRI) that can affect patients' health-related quality of life and cause disruptions to treatment. SWOG S1013 (NCT01416688) is a multi-center study designed to validate the Function...